FDA officials clarify how diversity action plans intersect with multiregional clinical trials

Regulatory NewsRegulatory NewsBiologics/ biosimilars/ vaccinesClinical TrialsDiversityGlobalGuidanceMedical DevicesPharmaceuticalsUnited StatesUS Food and Drug Administration (FDA)